Innate Pharma S.A. (IPHA)
| Market Cap | 641.08M |
| Revenue (ttm) | 58.80M |
| Net Income (ttm) | -92.11M |
| Shares Out | 79.15M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,372,967 |
| Open | 7.65 |
| Previous Close | 5.75 |
| Day's Range | 7.50 - 11.95 |
| 52-Week Range | 3.02 - 11.95 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 6.55 (-19.1%) |
| Est. Earnings Date | n/a |
About IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumo...
Financial Performance
In 2020, Innate Pharma's revenue was 70.45 million, a decrease of -17.90% compared to the previous year's 85.81 million. Losses were -63.98 million, 208.2% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 6.55, which is a decrease of -19.14% from the latest price.
News
Here's Why Innate Pharma Stock Is Rocketing Higher Today
A clinical trial with an experimental lung cancer drug produced some positive results.
What Is Happening With Innate Pharma Stock On Friday?
Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Onc...
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented re...
Monalizumab Data From COAST Trial Presented at ESMO Congress 2021
Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented r...
Innate Pharma Reports First Half 2021 Financial Results and Business Update
MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six month...
Innate Pharma reports first half 2021 financial results and business update
Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended ...
Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update
MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on We...
Why Innate Pharma Shares Are Rising On Friday?
Innate Pharma SA (NASDAQ:IPHA) stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late...
Monalizumab and ANKET™ Data Will be Presented at ESMO 2021 Virtual Congress
Marseille, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-break ing abstract on COAST Phase 2 trial
Monalizumab and ANKET™ Data Will Be Presented at ESMO 2021 Virtual Congress
AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial AstraZeneca to present new data on monalizumab in combination with durval...
Innate Pharma to Participate in Upcoming Investor Conferences
MARSEILLE, France, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior mana...
Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints
Innate Pharma SA (NASDAQ: IPHA) has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia did not meet its primary endpoints in all three cohorts trial. Bas...
Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia
Investigator-sponsored FORCE trial did not meet primary endpoints
Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia
Marseille, France, July 06, 2021 (GLOBE NEWSWIRE) -- Investigator-sponsored FORCE trial did not meet primary endpoints
Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients
Innate Pharma SA (NASDAQ: IPHA) has announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab. Data were shared at the International ...
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Company to highlight lacutamab data in mycosis fungoides and share data on...
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
Marseille, France, June 10, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced it will present the latest preclinica...
New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference...
First clinical data of mycosis fungoides presented from the TELLOMAK trial First clinical data of mycosis fungoides presented from the TELLOMAK trial
New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference...
First clinical data of mycosis fungoides presented from the TELLOMAK trial First clinical data of mycosis fungoides presented from the TELLOMAK trial
Outcome of Innate Pharma's Annual General Meeting
MARSEILLE, France, May 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders...
Innate Pharma Virtual 2021 Annual General Meeting
MARSEILLE, France, May 12, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bullet...
Innate Pharma First Quarter 2021 Report
MARSEILLE, France, May 11, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its revenue and cash position for...
Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update
MARSEILLE, France, May 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a co...
Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Re...
Marseille, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Univers...
Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021
The Annual General Meeting will be broadcasted live by the Company